Economic evaluation of pharmacogenomics: A value-based approach to pragmatic decision making in the face of complexity

Public Health Genomics

Volumn 17, Issue , 2014, Pages 256-264

  Snyder, Susan R ^a   Mitropoulou, Christina ^b   Patrinos, George P ^c   Williams, Marc S ^a  

^a GEISINGER MEDICAL CENTER   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Comparative effectiveness; Cost benefit analysis; Cost utility analysis; Decision making; Diagnostics; Economics; Personalized genomics; Value

Indexed keywords

ARTICLE; DECISION MAKING; ECONOMIC EVALUATION; HUMAN; PHARMACOGENOMICS; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION STUDY; HEALTH CARE DELIVERY; INTERPERSONAL COMMUNICATION; METHODOLOGY; PHARMACOGENETICS; PUBLIC HEALTH;

COMMUNICATION; COST-BENEFIT ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; HUMANS; PHARMACOGENETICS; PUBLIC HEALTH; RESEARCH DESIGN;

EID: 84919956669     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000366177     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention, Office of Public Health Genomics: Public health genomics: genetic testing: ACCE model list of 44 targeted questions aimed at a comprehensive review of genetic testing 2010. http:// www.cdc.gov/genomics/gtesting/ACCE/ acce-proj.htm (accessed July 15, 2014).
2. Koelsch C, Przewrocka J, Keeling P: Towards a balanced value business model for personalized medicine: an outlook. Pharmacogenomics 2013; 14: 89-102.
3. Annemans L, Redekop K, Payne K: Current methodological issues in the economic assessment of personalized medicine. Value Health 2013; 16(suppl 6):S20-S26.
4. Buchanan J, Wordsworth S, Schuh A: Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics 2013; 14: 1833-1847.
5. Ramaekers BL, Joore MA, Grutters JP: How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines. Value Health 2013; 16: 855-862.
6. Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J; Personalized Medicine Development and Reimbursement Working Group: Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health 2012; 15: 1162-1171.
7. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; CHEERS Task Force: Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care 2013; 29: 117-122.
8. Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P: The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 2014; 16: 251-257.
9. Khoury MJ, Clauser SB, Freedman AN, Gillanders EM, Glasgow RE, Klein WM, Schully SD: Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev 2011; 20: 2105-2114.
10. Grosse SD, Khoury MJ: What is the clinical utility of genetic testing? Genet Med 2006; 8: 448-450.
11. Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, Bick D, Bottinger EP, Brilliant MH, Eng C, Frazer KA, Korf B, Ledbetter DH, Lupski JR, Marsh C, Mrazek D, Murray MF, O'Donnell PH, Rader DJ, Relling MV, Shuldiner AR, Valle D, Weinshilboum R, Green ED, Ginsburg GS: Implementing genomic medicine in the clinic: the future is here. Genet Med 2013; 15: 258-267.
12. Johnson JA: Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics 2013; 14: 835-843.
13. Beitelshees AL, Veenstra DL: Evolving research and stakeholder perspectives on pharmacogenomics. JAMA 2011; 306: 1252-1253.
14. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD; ISPORSMDM Modeling Good Research Practices Task Force: Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health 2012; 15: 835-842.
15. Towse A, Barnsley P: Approaches to identifying, measuring, and aggregating elements of value. Int J Technol Assess Health Care 2013; 29: 360-364.
16. Thokala P, Duenas A: Multiple criteria decision analysis for health technology assessment. Value Health 2012; 15: 1172-1181.
17. Marsh K, Lanitis T, Neasham D, Orfanos P, Caro J: Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. Pharmacoeconomics 2014; 32: 345-365.
18. Williams MS: Genomic medicine implementation: learning by example. Am J Med Genet C Semin Med Genet 2014; 166C:8-14.
19. Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W: A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med 2010; 12: 686-693.
20. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team: HLA-B ∗ 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.
21. Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG: Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 2010; 28: 1025-1039.
22. Gambacorti-Passerini C: Part I: Milestones in personalised medicine - imatinib. Lancet Oncol 2008; 9: 600.
23. Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F: KRAS mutation confers resistance to antibody- dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer 2014; 134: 2146-2155.
24. Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL: KRAS p.G13d mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer 2013; 119: 714-721.
25. Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J, Malmström RE, Asola E, Baumgärtel C, Bennie M, Bishop I, Bucsics A, Campbell S, Diogene E, Ferrario A, Fürst J, Garuoliene K, Gomes M, Harris K, Haycox A, Herholz H, Hviding K, Jan S, Kalaba M, Kvalheim C, Laius O, Lööv SA, Malinowska K, Martin A, Mc-Cullagh L, Nilsson F, Paterson K, Schwabe U, Selke G, Sermet C, Simoens S, Tomek D, Vlahovic-Palcevski V, Voncina L, Wladysiuk M, van Woerkom M, Wong-Rieger D, Zara C, Ali R, Gustafsson LL: Personalizing health care: feasibility and future implications. BMC Med 2013; 11: 179.
26. Lee SH, Sim SH, Kim JY, Cha S, Song A: Application of cancer genomics to solve unmet clinical needs. Genomics Inform 2013; 11: 174-179.
27. Rubenstein JH, Vakil N, Inadomi JM: The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2005; 22: 135-146.
28. Gordon LG, Mayne GC, Hirst NG, Bright T, Whiteman DC; Australian Cancer Study Clinical Follow-Up Study, Watson DI: Costeffectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus. Gastrointest Endosc 2014; 79: 242-256 e246.
29. National Cancer Institute: What you need to know about cancer of the esophagus. 2013. http://www.cancer.gov/cancertopics/wyntk/ esophagus/page4 (accessed June 13, 2014).
30. National Cancer Institute: SEER stat fact sheets: esophageal cancer. 2014. http://seer. cancer.gov/statfacts/html/esoph.html (accessed June 13, 2014).
31. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE: Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572.
32. Hinojosa-Lindsey M, Arney J, Heberlig S, Kramer JR, Street RL Jr, El-Serag HB, Naik AD: Patients' intuitive judgments about surveillance endoscopy in Barrett's esophagus: a review and application to models of decisionmaking. Dis Esophagus 2013; 26: 682-689.
33. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
34. San Miguel R, Gimeno-Ballester V, Mar J: Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 387-402.
35. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
36. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S: Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28: 397-404.
37. Grol R, Wensing M: What drives change? Barriers to and incentives for achieving evidence- based practice. Med J Aust 2004; 180(suppl 6):S57-S60.
38. Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS; Cost Work Group, Third US Preventive Services Task Force: The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med 2001; 20: 36-43.
39. Eccles M, Mason J: How to develop cost-conscious guidelines. Health Technol Assess 2001; 5: 1-69.
40. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A: Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004; 8:iii-iv, 1-192.
41. Evaluation of Genomic Applications in Practice Prevention (EGAPP) Working Group: Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009; 11: 35-41.
42. Mvundura M, Grosse SD, Hampel H, Palomaki GE: The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010; 12: 93-104.
43. Gudgeon JM, Williams JL, Burt RW, Samowitz WS, Snow GL, Williams MS: Lynch syndrome screening implementation: business analysis by a healthcare system. Am J Manag Care 2011; 17:e288-e300.
44. Gudgeon JM, Belnap TW, Williams JL, Williams MS: Impact of age cutoffs on a Lynch syndrome screening program. J Oncol Pract 2013; 9: 175-179.
45. Mitropoulos K, Johnson L, Vozikis A, Patrinos GP: Relevance of pharmacogenomics for developing countries in Europe. Drug Metabol Drug Interact 2011; 26: 143-146.
46. Mitropoulou C, Fragoulakis V, Bozina N, Vozikis A, Supe S, Bozina T, Poljakovic Z, van Schaik RH, Patrinos GP: Economic evaluation for pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics, in press.
47. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W: Relationship between the HLA-B ∗ 1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013; 149: 1025-1032.
48. Dong D, Sung C, Finkelstein EA: Cost-effectiveness of HLA-B ∗ 1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2012; 79: 1259-1267.
49. Mizzi C, Mitropoulou C, Mitropoulos K, Peters B, Agarwal MR, van Schaik RH, Drmanac R, Borg J, Patrinos GP: Personalized pharmacogenomics profiling using whole genome sequencing. Pharmacogenomics 2014;15:1223-1234.